These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on Werner RA; Bundschuh RA; Bundschuh L; Javadi MS; Leal JP; Higuchi T; Pienta KJ; Buck AK; Pomper MG; Gorin MA; Lapa C; Rowe SP J Nucl Med; 2018 Dec; 59(12):1857-1864. PubMed ID: 30190304 [TBL] [Abstract][Full Text] [Related]
10. High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with Werner RA; Habacha B; Lütje S; Bundschuh L; Higuchi T; Hartrampf P; Serfling SE; Derlin T; Lapa C; Buck AK; Essler M; Pienta KJ; Eisenberger MA; Markowski MC; Shinehouse L; AbdAllah R; Salavati A; Lodge MA; Pomper MG; Gorin MA; Bundschuh RA; Rowe SP Mol Imaging; 2022; 2022():7056983. PubMed ID: 35283693 [TBL] [Abstract][Full Text] [Related]
11. Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PET. Leung KH; Rowe SP; Leal JP; Ashrafinia S; Sadaghiani MS; Chung HW; Dalaie P; Tulbah R; Yin Y; VanDenBerg R; Werner RA; Pienta KJ; Gorin MA; Du Y; Pomper MG EJNMMI Res; 2022 Dec; 12(1):76. PubMed ID: 36580220 [TBL] [Abstract][Full Text] [Related]
12. The significance of equivocal bone findings in staging PSMA imaging in the preoperative setting: validation of the PSMA-RADS version 1.0. Kuten J; Dekalo S; Mintz I; Yossepowitch O; Mano R; Even-Sapir E EJNMMI Res; 2021 Jan; 11(1):3. PubMed ID: 33409930 [TBL] [Abstract][Full Text] [Related]
13. Agreement between PSMA-RADS and E-PSMA systems in classifying [ Mendoza-Ávila M; Esparza-Pérez H; Castillo-López JA; Rodea-Montero ER Front Med (Lausanne); 2024; 11():1368093. PubMed ID: 38545506 [TBL] [Abstract][Full Text] [Related]
14. PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer. Rowe SP; Macura KJ; Mena E; Blackford AL; Nadal R; Antonarakis ES; Eisenberger M; Carducci M; Fan H; Dannals RF; Chen Y; Mease RC; Szabo Z; Pomper MG; Cho SY Mol Imaging Biol; 2016 Jun; 18(3):411-9. PubMed ID: 27080322 [TBL] [Abstract][Full Text] [Related]
15. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer. Amin A; Blazevski A; Thompson J; Scheltema MJ; Hofman MS; Murphy D; Lawrentschuk N; Sathianathen N; Kapoor J; Woo HH; Chalasani V; Rasiah K; van Leeuwen PJ; Tang R; Cusick T; Stricker P; Emmett L BJU Int; 2020 Apr; 125(4):515-524. PubMed ID: 31957122 [TBL] [Abstract][Full Text] [Related]
16. Single-Center Comparison of [ Mirzaei S; Lipp R; Zandieh S; Leisser A Curr Oncol; 2021 Oct; 28(5):4167-4173. PubMed ID: 34677271 [TBL] [Abstract][Full Text] [Related]